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Pathophysiological Changes and 
Systemic Inflammation in Brain 




Transplantation is the definitive treatment of end-stage organ disease. As the 
shortage of suitable organs poses its main limitation, the active management of 
potential organ donors becomes increasingly more important. The majority of solid 
organs are still obtained from donors after confirmed brain death. Brain death is 
the complete and irreversible cessation of all brain functions, and triggers a variety 
of severe pathophysiological changes in cardiovascular, hormonal and metabolic 
status that can result in organ damage. Moreover, brain death is associated with 
massive inflammatory response with a cytokine storm and complement activation 
that increases graft immunogenicity and adversely affects graft survival. Organs 
from brain-dead donors are more prone to graft dysfunction and rejection when 
compared to organs obtained from living donors. Brain death is thus believed to be 
an important risk factor influencing the quality of organs before procurement.
Keywords: inflammation brain death, pathophysiology brain death, systemic 
inflammation brain death, SIRS, donation after brain death, brain death, organ 
donation
1. Introduction
Transplantation is the definitive treatment for solid organ end-stage disease. The 
waiting list for organ transplant is growing rapidly and the available offer of suit-
able organs is not sufficient enough to satisfy the needs. Within the Eurotransplant 
region and worldwide, the majority of transplanted organs are obtained from 
deceased brain-dead donors [1].
It is well known that the results from kidney grafts retrieved from living donors 
(both related and unrelated to recipients) are far superior to those of deceased 
organ donors in terms of delayed graft function, acute rejection and graft survival 
[2–4]. As there is a significant difference between short- and long-term survival 
of kidneys from living and deceased donors, the focus has recently shifted from 
recipient to donor and the events occurring at the time of and after brain death.
Brain death is a catastrophic event resulting in severe systemic disturbance 
including haemodynamic instability, inflammatory, hormonal, metabolic and 
hematological disorders [5]. A limiting factor for better transplant outcome in a 
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potential organ donor is definitely activation of the immune system that starts early, 
during and immediately after brain death. For this reason, brain death has become 
one of the key factors believed to significantly impact transplant function and 
survival.
Early identification of potential donors is essential to establish timely and 
aggressive donor management so as to provide the quantity and quality of organs 
available for successful donation and transplantation. Unfortunately, no standard-
ized guidelines for the management of brain-dead donors have been implemented 
to this moment [6]. Nevertheless, the main goal for successful organ donation 
is to normalize and maintain the physiological conditions, including haemody-
namic stability, adequate oxygenation, and optimal fluid and electrolyte balance. 
Aggressive respiratory and haemodynamic monitoring is thus essential to prevent 
any unnecessary loss of organs [7].
2. Brain death-related pathophysiological systemic disorders
Brain death is a complete cessation of all brain functions, including the brain 
stem, when the etiology of brain dysfunction is known and considered irreversible. 
All reversible causes must be examined and excluded. The essential criteria for 
brain death, according to the American Academy of Neurology (AAN), are coma or 
unresponsiveness, absence of brain stem reflexes, and apnea. A patient determined 
to be brain dead is legally and clinically dead, and can be considered as organ donor 
in agreement with his own and his next of kin’s choice [5]. Loss of central regulation 
leads to severe pathophysiological alterations in haemodynamics and the respiratory, 
inflammatory and endocrine systems [7, 8].
2.1 Cardiovascular changes
The increased intracranial pressure following cerebral trauma, infarction 
or hemorrhage causes increased arterial blood pressure as an attempt to restore 
adequate cerebral perfusion. In case this fails, ischemia of pons generates a reflex 
response, known as Cushing reflex, with bradycardia and hypertension. The 
ischemic damage then progresses through the entire brain and results in sym-
pathetic stimulation and a catecholamine storm characterized by hypertension, 
tachycardia, and severe peripheral vasoconstriction. A more explosive increase 
of intracranial brain pressure correlates with a higher increase in catecholamine 
concentrations. Consequently, a significant reduction in blood flow prevails 
despite increased systemic perfusion pressure, and leads to visceral and myocardial 
ischemia [8, 9]. Observations in brain-dead donors show evidence of myocardial 
ischemia on echocardiographic exam [10, 11].
The initial phase of a catecholamine storm is followed by a loss of sympathetic 
tonus and profound vasodilation due to ischemia of the brain stem vasomotor 
nuclei. Many factors contribute to hypotension, including vasodilatation, catechol-
amine depletion, myocardial dysfunction, relative hypovolemia, and endocrine 
dysfunction. Hypoperfusion further deteriorates organ integrity and, together with 
a catecholamine explosion, leads to deleterious consequences for potential grafts if 
left untreated.
2.2 Pulmonary changes
Two main complications related to brain death-induced lung injury and dys-
function are neurogenic pulmonary edema and inflammatory acute lung injury. 
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Donors may also have specific pulmonary damage, including aspiration, atelectasis, 
contusion, chest trauma, or infection [12]. Volume overload after fluid resuscita-
tion, also due to profound hypotension, increases the risk of pulmonary edema [8].
2.3 Endocrine system, stress and metabolic responses
Diabetes insipidus secondary to posterior pituitary infarction and lack of anti-
diuretic hormone results in electrolyte imbalance, hypovolemia, and circulatory 
instability. Thyroid hormonal changes and thyroid-stimulating hormone (TSH) 
levels show the typical picture of euthyroid sick syndrome. Temperature regulation 
in the hypothalamus is affected, manifesting with initial hyperthermia followed by 
hypothermia. Hypothermia, additionally worsened by peripheral vasodilatation, 
further aggravates acidosis and increases the risk for arrhythmias and cold-induced 
diuresis. Due to reduced insulin concentration and peripheral insulin resistance, 
hyperglycaemia is common [7, 12].
2.4 Hematological changes
Damaged brain tissue is a rich source of potent platelet-activating and proco-
agulant molecules, which often leads to disseminated intravascular coagulation. 
Hypothermia, acidosis and catecholamines all affect platelets function, further 
contributing to coagulopathy [13, 14].
3. Strategies to maintain pathophysiological changes in organ donors
The current recommendations and guidelines for the management of a potential 
organ donor in the intensive care unit (ICU) are based on pathophysiological reasoning 
and experience gained from general ICU management strategies, and not on evidence 
from randomized controlled trials (Table 1) [17]. The protection and optimization 
of organ functions in order to provide for a maximum number of quality organs that 
can be offered for donation is the essential goal of intensive care donor management. 
The purpose of this paper is not to describe the management of the donor in detail, as 
this was already summarized recently by Meyfroidt et al. [18]. A more simplified and 
easy-to-remember series of goals was established a decade ago, known as the “rule of 
100”: systolic arterial pressure > 100 mmHg, urine output >100 ml/hr., arterial partial 
pressure of oxygen (PaO2) >100 mmHg, hemoglobin concentration > 100 g/L, and 
blood sugar 100% normal [15].
4. Activation of inflammatory system
Aseptic necrosis of brain tissue leads to the release of numerous inflammatory 
mediators that trigger and support massive local and systemic inflammatory response 
driven by both the innate and adaptive immune systems. Catecholamine storm and 
hypotension with hypoperfusion of organs then contribute to the additional activa-
tion of immunologic pathways [19].
One of its harmful consequences is the activation of the cytokine system, poly-
peptide immunomodulatory molecules that participate in both immune responses 
and act on cell differentiation, proliferation and activity. Several cytokines have 
been found in brain tissue and cerebrospinal fluid after brain death. These cyto-
kines are then delivered into circulation through a faulty blood–brain barrier, and 
continue to stimulate peripheral target cells and organs [20].
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Suggested approach
General care Manage in ICU. Central and arterial line insertion and monitoring of central venous 
and arterial pressure. Cardiac output monitoring preferred. Nasogastric tube 
insertion. Foley’s catheter insertion and measurement of urine output.
Reduce heat loss and actively warm, if necessary, to maintain core temperature 
>35°C. Actively treat infections. Frequent airway suctioning. Maintain pneumatic 
compression device for preventing deep vein thrombosis. Eye protection. Ulcer 
prophylaxis. Broad spectrum antibiotics.
Respiratory Use ‘lung protective’ ventilation (lowest possible plateau pressure, tidal volumes of 6 
ml/kg of ideal body weight, and moderate positive end expiratory pressure [PEEP] 
of 5–10 cmH2O to achieve an oxygen saturation >92%). The respiratory passage must 
be kept clear of any obstruction with routine measures. Avoid the administration of 
excessive i.v. fluids.
Cardiovascular Goals for the management of haemodynamic status in donors: (1) to maintain 
normovolaemia; (2) control blood pressure (BP); (3) optimize cardiac output and 
maintain perfusion pressure of all organs; and (4) to minimize the use of vasoactive 
agents.
Review fluid balance and correct hypovolaemia. Monitor cardiac output to titrate 
fluids and inotropic/vasopressor drugs to intended goals. At present, there are no 
convincing studies or consensus to demonstrate that one vasopressor is superior to 
another, and different drugs (noradrenaline, adrenaline, vasopressin, dopamine, 
and/or dobutamine) are used, depending on local practices and protocols. High doses 




Administer maintenance fluids, preferentially crystalloids with balanced salt content 
(lactated Ringer’s solution and half-normal saline (0.45%) are most frequently used) 
to avoid hypernatremia. Avoid volume overload. Correct electrolyte abnormalities to 
normal values. Blood glucose target concentrations 4–8 mmol/ litre.
A solution of 0.9% normal saline may cause hyperchloremic acidosis, which increases 
renal vascular resistance. Colloids, such as hydroxyethyl starches, need to be avoided 
in organ donors, as they can damage renal epithelial cells and cause early graft 
dysfunction in the transplanted kidneys. Albumin solutions can be used to reduce the 
amount of fluid volume administered.
Blood and 
coagulation
Consider the need for transfusion. The target is to maintain the hematocrit above 
30%.
Maintain thromboprophylaxis, as there is a high incidence of embolisms.
Coagulopathy should be treated promptly with management, including the 
administration of red blood cells, clotting factors, and platelets.
Systemic effects Corticosteroids. The main purpose of using corticosteroids is not to treat 
adrenocortical failure, but rather to attenuate the immune responses and reduce the 
catecholamine requirement for maintaining BP. Methylprednisolone 15 mg kg−1 bolus 
is recommended immediately after brain death is confirmed.
Triiodothyronine. Routine replacement of thyroid hormones is not recommended 
for all organ donors, but only if impaired cardiac performance is documented despite 
overall good general management and in case of patients with true hypothyroidism.
Insulin. Hyperglycemia is closely associated with reduced host immune responses 
that result in an increased risk of infection, worsening of renal function in renal 
transplant recipients, as well as osmotic diuresis [16]. Hyperglycemic organ donor 
patients should be treated according to the local institutional guidelines used for other 
critically ill patients.
Anti-diuretic hormone. If the patient develops diabetes insipidus, the condition can 
be treated by the replacement of fluid with adequate crystalloid solutions. However, 
if hypotension persists despite adequate volume resuscitation in the absence of other 
causes, treatment with vasopressin or DDAVP should be considered.
DDAVP, 1-deamino-8-D-arginine-vasopressin; PEEP, positive end-expiratory pressure.
Table 1. 
Summary of the principles of donor management (adapted from Anwar et al. [7] and McKeown et al. [15]).
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The up-regulated expression of cell adhesion molecules (CAMs), including 
selectines, vascular (VCAM-1) and intracellular CAMs (ICAM-1) on the endothe-
lium of potential grafts plays a critical role in numerous inflammatory processes. 
One of their tasks is the recruitment of circulating monocytes, macrophages and 
polymorphonuclear leukocytes as shown in organ biopsies after organ retrieval 
[12, 16, 21, 22]. Therefore, unsurprisingly, increased levels of CAMs have been 
associated with increased mortality in transplant recipients [16].
The activation of leukocyte populations in peripheral organs further maintains 
an inflammatory environment by expressing CAMs and releasing proinflammatory 
substances, among others, tumor necrosis factor alpha (TNF-α) and interferon 
gamma (IFN-γ) [16]. Especially IFN-γ induces the expression of major histo-
compatibility complex (MHC) classes I and II on graft cells, which potentiate the 
immunogenicity of organs via the T-cell recognition process. The activated organs 
provoke a host immune system after engraftment, resulting in severe acute or 
chronic rejection [23].
Complement activation has already been demonstrated in ischemia–reperfusion  
injury and rejection. Fragments of complement activation products have been 
measured in plasma and organ biopsies. Their values were higher compared to living 
donors [24–26].
4.1 Cytokines implicated in brain death
Increased blood levels of several cytokines, such as TNF-α, interleukin (IL)-6, 
IL-8, IL-1β, and IL-2R, have been observed after brain death [27, 28]. Cytokines 
derive mostly from T-cells and are classified into different groups according to their 
main function and T helper (Th) cell subtypes to which they are related.
The Th1-cell related cytokines are TNF-α, IL-1, IL-2, IL-12 and IFN-γ [29, 30]. 
They act early in the inflammatory cascade and stimulate and support the inflam-
mation by mediating between different inflammatory pathways; they activate endo-
thelial cells and cellular adhesion molecules, and contribute to T-cell maturation.
The Th2-cell-related cytokines IL-4, IL-5, IL-10 and IL-13 are not as significant 
and are considered to be anti-inflammatory when related to brain death and the 
early transplant period [19, 31, 32].
One of the most heavily implicated cytokines in brain death is IL-6, a member 
of Th-17 cell related mediators [33, 34]. Increased concentrations of IL-6 have 
been demonstrated both in plasma and organs of brain-dead donors, including the 
kidneys, lungs, liver and heart [34–36]. Higher values of IL - 6 are associated with 
worse transplantation outcomes and poorer survival of recipients [33, 37].
A significant increase in IL-8 values in the bronchoalveolar lavage fluid from 
brain-dead lung donors has been demonstrated and correlates with early graft dys-
function after lung transplant [38]. In addition, elevated IL-6 gene expression was 
observed in the preimplantation biopsies of patients who died within 30 days after 
lung transplant [39]. Furthermore, the levels of IL-1β and TNF-α were significantly 
higher in donor lungs rejected for transplantation compared to transplanted lungs 
[40]. The values of IL-6 and TNF-α in the myocardium of dysfunctional discarded 
donor hearts were higher than in transplanted donor hearts [41].
4.2 Role of complement
The complement cascade is an important part of the innate immune system 
and transplantation process. Activation of either the classic, alternative or lectin 
pathway of the complement system leads to the formation of a common terminal 
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cell lytic complex or C5b-9, also known as membrane attack complex (MAC). MAC 
induces complement-mediated lysis of cells. Proteolytic complement fragments 
such as C5a, C3a and, to a lesser extent, C4a, further induce acute inflammation by 
activating mast cells, neutrophils and endothelial cells.
Studies have shown that all three pathway types are involved in systemic inflam-
mation secondary to brain death [24]. Complement activation products have the 
ability to produce proinflammatory substances, including cytokines, and act as 
chemotactic factors for leukocytes.
In deceased brain donors, the increased complement plasma levels of C5b9 were 
higher than in the plasma of living organ donors. Higher levels of C5b9 in deceased 
brain-dead and deceased cardiac-dead donors were associated with worse tissue 
damage, a higher rate of acute and chronic rejection, and inferior function after 
transplantation [25].
Complement activation also results in the release of anaphylatoxins C3a and C5a, 
potent activators of T-cells. Brain-dead organ donors had higher values of C5a in 
plasma compared to living donors [26].
5. Inflammation limiting strategies
5.1 Inflammation limiting strategies in organ donors
The use of methylprednisolone, alone or as part of hormonal replacement, 
reduces the immunological activation observed after brain death in terms of 
decreasing cytokine production and preventing alterations induced by proinflam-
matory mediators [36, 42]. In a prospective randomized study, reduced serum 
and graft cytokine expression and improved graft function in human liver trans-
plantation was found/reported after methylprednisolone administration [42]. 
Inflammation in the heart and kidneys is also reduced. The reduction in cytokine 
activation is almost comparable to the levels seen in living donor transplantation 
[36]. Methylprednisolone use is associated with increased organ retrieval and 
improved short- and long-term outcome for most transplanted organs [12].
Numerous other agents and approaches are currently under investigation as part 
of organ protection and preservation strategies.
Among such strategies, active removal of cytokines by haemoadsorption was 
shown to be feasible, leading to at least a moderate fall in cytokine concentration in 
circulation, attenuating the inflammatory response associated with brain death [9].
Although no RCTs in humans currently exist, animal models have also demon-
strated a reduced inflammatory response and improved oxygenation when using 
noradrenaline [43, 44].
Since glucagon-like peptide-1 (GLP1) analogues were shown to possess interest-
ing cytoprotective effects in different liver and pancreatic disease models, these 
molecules were also tested in experimental transplantation models. Treatment 
with the GLP1 analogue exendin-4 (Ex-4) relieved brain dead-induced liver [45], 
renal [46] and pancreatic islet injury [47] through alleviation of inflammation and 
oxidative stress.
After single administration of antithymocyte globulin (ATG) to brain-dead 
mice, the inflammatory reaction in the myocardium showed a significant reduction 
in IL-2 expression and the reduction of IL-6 deposition in media cells in ATG-
treated specimens compared to controls [48].
Targeting complement activation after the induction of brain death also reduced 
renal inflammation and improved renal function before transplantation in animal 
models [49]. Recently, a study by Jager et al. [50]. has shown that experimental 
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donor rat pre-treatment with anti-FB preserved renal function reduced renal dam-
age and inflammation prior to transplantation. Seemingly, high-dose C1-INH treat-
ment of brain-dead rat donors resulted in significantly lower renal gene expression 
and serum levels of IL-6, which reflected with improved renal function and reduced 
renal injury [51].
Traumatic brain injury and other inflammatory conditions are currently being 
treated in preclinical and clinical trials by a number of cellular therapies, among 
which mesenchymal stem cells (MSC) are of greatest interest due to their wide-
spread usage and ease to isolate and culture [52, 53].
Therefore, strategies targeting cytokine and complement activation in human 
brain-dead donors pose as a new and promising opportunity to improve organ 
quantity and quality for successful organ donation and transplantation outcome.
5.2 Inflammation limiting strategies to preserve procured organs
After procurement, organs are further exposed to injury due to removal 
from their physiological conditions. Hypoxic injury has a detrimental effect on 
organ structure and function, and adds to increased immunogenicity. Prolonged 
ischemia, cold or warm, is a risk factor for early graft dysfunction and worse 
long-term outcomes. The duration and type (warm or cold) of ischemia time 
may also directly influence cytokine production [19]. Significant cytokine gene 
expression has otherwise already occurred directly after brain death. Namely, 
the cytokine gene expression before transplantation was shown to be even higher 
than during the period of acute rejection [35]. A strong association was recently 
identified between cold ischemia time and the levels of IL-1 and IL-8 in human 
liver transplants. Warm ischemia time also correlated with IL-6 and IL-10 in the 
same study [54].
Successful preservation strategies are key to minimize ischemic damage and the 
effect of reperfusion with associated increased immunogenicity after organ implan-
tation. The current accepted standard for most solid organs is static cold storage 
(SCS), where the solid organ is stored on ice after removal from the donor, and then 
removed from the ice box at the time of implantation. However, novel technologies 
enable perfusion of the donated organ during the transport phase or at the recipient 
centre, with the option to use a variety of temperatures and different perfusates. 
Machine perfusion systems (hypothermic, normothermic, oxygen persufflation) 
represent dynamic preservational methods.
Hypothermic preservation strategies are now widely used to decrease inflamma-
tion, depress the metabolic rate of cells, and reduce the effects of ischemia [55, 56]. 
In the largest meta-analysis performed so far [57], hypothermic machine perfusion 
(HMP) was superior to SCS in deceased donor kidney transplantation (this was 
true for both DBD and DCD kidneys). The incidence of delayed graft function in 
kidneys from deceased brain donors was much lower in the group with hypothermic 
perfusion. Additionally, reports of economic analysis suggested that HMP can lead 
to cost savings in both North American and European settings.
Since very low temperatures can also have harmful repercussions on organs in 
terms of cytokine and reactive oxygen production [58], over the last two decades 
several research groups have examined the effects of increasing the temperature 
of machine perfusion to near-normothermic temperatures (20–33°C). Near-
normothermic preservation is particularly applicable for organs of marginal donors 
or donors after cardiac death. In these cases, due to prolonged warm ischemia times, 
organ viability is negatively impacted by the subsequent cold preservation. Hence, 
normothermic perfusion may enhance preservation and transplantation outcomes 
and reduce the risk of non-functional organs [59].
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6. Conclusion
Brain-dead organ donors represent the major source of organs for organ 
transplantation. The path from a brain-dead potential donor to a favorable graft 
and recipient outcome is long, and can have a cardinal impact on the quality of 
transplanted organs. Brain death-related systemic changes can damage the organs 
to the point where donation is not possible. Severe systemic inflammatory response 
enhances graft immunogenicity and affects graft survival and transplant outcome. 
Thus, immunomodulatory agents can become pivotal in donor procurement and 
preservation in future.
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